Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

Phase 2

Completed

• Conditions: Type 2 Diabetes Mellitus
• Interventions: Drug: Colesevelam hydrochloride; Drug: placebo

• Registration Number: NCT00361153
• Lead Sponsor: Daiichi Sankyo

Brief Summary

This study is designed to test whether WelChol (colesevelam HC1) improves blood sugar control in patients with type 2 diabetes by making their own insulin work more efficiently.

Detailed Description

Single-center, randomized, parallel, double-blind, placebo controlled, 8-week trial in subjects with type 2 diabetes mellitus. Two parallel treatment groups include double-blind colesevelam or placebo. A screening period may be up to 18 weeks to withdraw non sulfonylurea antidiabetic treatment or withdraw or adjust sulfonylurea antidiabetic treatment. To evaluate hepatic and peripheral insulin sensitivity, subjects will undergo a two-step hyperinsulinemic-euglycemic clamp with a tritiated glucose infusion at pre randomization and after 8 weeks of treatment. To evaluate oral glucose absorption, subjects will undergo two oral glucose tolerance tests (OGTT) at pre randomization, one without colesevelam and one with colesevelam, and one OGTT at the end of the treatment period..

Study Timeline

• Study Start: 2006-05
• Study First Submitted: 2006-08-03
• Study First Submitted QC: 2006-08-03
• Study First Posted: 2006-08-07
• Primary Completion: 2006-10
• Study Completion: 2007-03
• Status Verified: 2008-06
• Last Update Submitted: 2008-06-24
• Last Update Posted: 2008-06-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

Subjects meeting the following criteria at the Screening Visit will be eligible to participate in the trial:

• Have given written informed consent
• Ages 18 to 75 years, inclusive
• Diagnosis of type 2 diabetes mellitus of at least 3 months duration
• HbA1C 7.0- 10.0%, inclusive
• Antidiabetic treatment may include oral agents; all antidiabetic agents must be withdrawn before randomization
• Women may be enrolled if they are not pregnant (negative serum βHCG at the Screening Visit), are not breast-feeding, and do not plan to become pregnant during the trial. In addition, they must either have had a hysterectomy or tubal ligation at least 6 months before signing informed consent, be post-menopausal for 1 year, or practicing an acceptable method of birth control. An acceptable method of birth control may be oral, injectable or implantable hormonal contraceptives, intrauterine device, diaphragm plus spermicide, or female condom plus spermicide. Abstinence, partner's use of condoms, and partner's vasectomy are NOT acceptable methods of contraception
• BMI 25 - 45 kg/M sq, inclusive

Exclusion Criteria

Subjects are excluded from participation in the study if any of the following criteria apply:

• Type 1 diabetes mellitus or history of diabetic ketoacidosis
• Treatment with lipid or blood pressure lowering therapy that has not been stable for three months before randomization
• Treatment with WelChol, cholestyramine or colestipol for hyperlipidemia within the last 3 months
• Treatment with thiazolidinediones
• History of dysphagia, swallowing disorders, or intestinal motility disorder
• Serum triglyceride >500 mg/dL at Visit 1
• Serum LDL-C <60 mg/dL at Visit 1
• Any condition or therapy which, in the opinion of the investigator, poses a risk to the subject or makes participation not in the subject's best interest
• Use of any investigational drug within 30 days before randomization
• Chronic treatment with oral corticosteroids
• History of hyperthyroidism and/or treatment with thyroid hormone/ levothyroxine

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Colesevelam hydrochloride	Colesevelam hydrochloride
2	placebo	placebo

Primary Outcome Measures

Name	Time	Method
To evaluate the effect of 8 weeks treatment with WelChol on insulin sensitivity,as measured by the hyperinsulinemic-euglycemic clamp method, i.e., placebo-corrected change from baseline in M-value.	8 weeks

Secondary Outcome Measures

Name	Time	Method
To evaluate the effect of 2 weeks treatment with WelChol on insulin sensitivity,as measured by the hyperinsulinemic-euglycemic clamp method.	2 weeks
To evaluate acute and chronic effects of treatment with WelChol on plasma glucose after ingestion of a standard meal replacement.	8 weeks
To evaluate the effect of treatment with WelChol on HbA1C, insulin, fasting plasma glucose, and fructosamine.	8 weeks

Trial Locations

Locations (1)

Diabetes and Glandular Research Associates; 🇺🇸 San Antonio, Texas, United States